Table 1.

Patient demographics and baseline characteristics

Characteristics	5 mg (n = 1)	15 mg (n = 8)	30 mg (n = 5)	All (n = 14)
Age, years
Median	33.0	47.4	46.4	46.0
Range	33–33	39–52	34–69	33–69
Sex, n (%)
Male	1 (100.0)	4 (50.0)	4 (80.0)	9 (64.3)
Female	0	4 (50.0)	1 (20.0)	5 (35.7)
Tumor type, n (%)
High-grade glioma	1 (100.0)	7 (87.5)	5 (100.0)	13 (92.9)
WHO grade III astrocytoma	1 (100.0)	2 (25.0)	1 (20.0)	4 (28.6)
WHO grade IV glioblastoma	0	1 (12.5)	3 (60.0)	4 (28.6)
WHO grade III oligodendroglioma	0	2 (25.0)	0	2 (14.3)
WHO grade II to III astrocytoma	0	2 (25.0)	0	2 (14.3)
WHO grade III to IV glioma	0	0	1 (20.0)	1 (7.1)
Solid tumor	0	1 (12.5)	0	1 (7.1)
Colorectal cancer	0	1 (12.5)	0	1 (7.1)
Prior systemic therapy, n (%)
1	0	a2 (25.0)	1 (20.0)	3 (21.4)
2	1 (100.0)	1 (12.5)	2 (40.0)	4 (28.6)
≥ 3	0	5 (62.6)	2 (40.0)	7 (50.0)

^aNote: one patient did not have data regarding history of prior antitumor treatments.